Curated safety summary

MDMA for PTSD: adverse events

MDMA safety reports for PTSD most often include headache, insomnia, anxiety, fatigue among the source-backed named adverse events currently normalized in Blossom.

Papers with named AEs

Named AE rows

176

Source papers

Residual papers

How to read this summary

This page summarizes named adverse-event rows extracted from published paper, supplement, and registry evidence. It is intended as an evidence navigation aid and should not be read as a formal pharmacovigilance estimate or direct cross-trial comparison.

Most commonly reported named events

Counts are aggregated from source-backed named adverse-event rows. Denominators are shown only where the source row reported or clearly inherited one.

Back to evidence set →

Event	Aggregate count	Rate	Papers	Source terms
headache	232/356	65.2%	10	Headache
insomnia	139/341	40.8%	9	Insomnia
anxiety	114/356	32%	9	Anxiety
fatigue	110/356	30.9%	10	Fatigue
dizziness	98/655	15%	7	Dizziness
nausea	93/356	26.1%	9	Nausea
abdominal discomfort	74/653	11.3%	7

headache

headache was captured in 10 source papers (232/356). Interpret this as a source-backed named-event summary, not a head-to-head safety comparison.

MDMA-assisted therapy|33/46| 71.7%| during treatment

Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder

registry:self-compassion-mediates-treatment-effects-in-mdma-assisted-therapy-for-posttrau:NCT03537014:ctg-api

ClinicalTrials.gov adverse events: Headache 33/46 (71.7%) in MDMA-assisted Therapy.

MDMA-assisted therapy|33/46| 71.7%| during treatment

Effects of MDMA-assisted therapy for PTSD on self-experience

registry:self-experience-in-mdma-assisted-therapy-of-ptsd:NCT03537014:ctg-api

ClinicalTrials.gov adverse events: Headache 33/46 (71.7%) in MDMA-assisted Therapy.

MDMA-assisted therapy|33/46| 71.7%| during treatment

Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD

registry:pilot-study-suggests-dna-methylation-of-the-glucocorticoid-receptor-gene-nr3c1-i:NCT03537014:ctg-api

Limitations

Counts are aggregated from source-backed named adverse-event rows and may mix event windows, arms, and safety populations when papers report them differently.
Papers still in the named-AE residual blocker queue are not interpreted as event absence.
Denominators are included only when the source row reported or clearly inherited one.
This summary is a curated navigation layer, not a substitute for paper-level safety review.